Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1960 2
1961 1
1962 1
1963 5
1964 1
1966 1
1982 2
1986 1
1995 2
1997 2
2000 1
2001 2
2002 3
2003 1
2004 2
2005 3
2006 1
2007 2
2008 5
2009 9
2010 14
2011 16
2012 14
2013 7
2014 13
2015 13
2016 11
2017 18
2018 23
2019 17
2020 24
2021 24
2022 14
2023 16
2024 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

235 results

Results by year

Filters applied: . Clear all
Page 1
Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study.
Azoulay É, Castro P, Maamar A, Metaxa V, de Moraes AG, Voigt L, Wallet F, Klouche K, Picard M, Moreau AS, Van De Louw A, Seguin A, Mokart D, Chawla S, Leroy J, Böll B, Issa N, Levy B, Hemelaar P, Fernandez S, Munshi L, Bauer P, Schellongowski P, Joannidis M, Moreno-Gonzalez G, Galstian G, Darmon M, Valade S; Nine-I investigators. Azoulay É, et al. Lancet Haematol. 2021 May;8(5):e355-e364. doi: 10.1016/S2352-3026(21)00060-0. Lancet Haematol. 2021. PMID: 33894170 Free article.
Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial.
Blay JY, Chevret S, Le Cesne A, Brahmi M, Penel N, Cousin S, Bertucci F, Bompas E, Ryckewaert T, Soibinet P, Boudou-Rouquette P, Saada Bouzid E, Soulie P, Valentin T, Lotz JP, Tosi D, Neviere Z, Cancel M, Ray-Coquard I, Gambotti L, Legrand F, Lamrani-Ghaouti A, Simon C, Even C, Massard C. Blay JY, et al. Among authors: legrand f. Lancet Oncol. 2023 Aug;24(8):892-902. doi: 10.1016/S1470-2045(23)00282-6. Epub 2023 Jul 7. Lancet Oncol. 2023. PMID: 37429302 Clinical Trial.
Rapid GPR183-mediated recruitment of eosinophils to the lung after Mycobacterium tuberculosis infection.
Bohrer AC, Castro E, Tocheny CE, Assmann M, Schwarz B, Bohrnsen E, Makiya MA, Legrand F, Hilligan KL, Baker PJ, Torres-Juarez F, Hu Z, Ma H, Wang L, Niu L, Wen Z, Lee SH, Kamenyeva O; Tuberculosis Imaging Program; Kauffman KD, Donato M, Sher A, Barber DL, Via LE, Scriba TJ, Khatri P, Song Y, Wong KW, Bosio CM, Klion AD, Mayer-Barber KD. Bohrer AC, et al. Among authors: legrand f. Cell Rep. 2022 Jul 26;40(4):111144. doi: 10.1016/j.celrep.2022.111144. Cell Rep. 2022. PMID: 35905725 Free PMC article.
Benralizumab for PDGFRA-Negative Hypereosinophilic Syndrome.
Kuang FL, Legrand F, Makiya M, Ware J, Wetzler L, Brown T, Magee T, Piligian B, Yoon P, Ellis JH, Sun X, Panch SR, Powers A, Alao H, Kumar S, Quezado M, Yan L, Lee N, Kolbeck R, Newbold P, Goldman M, Fay MP, Khoury P, Maric I, Klion AD. Kuang FL, et al. Among authors: legrand f. N Engl J Med. 2019 Apr 4;380(14):1336-1346. doi: 10.1056/NEJMoa1812185. N Engl J Med. 2019. PMID: 30943337 Free PMC article. Clinical Trial.
Involvement of eosinophils in the anti-tumor response.
Gatault S, Legrand F, Delbeke M, Loiseau S, Capron M. Gatault S, et al. Among authors: legrand f. Cancer Immunol Immunother. 2012 Sep;61(9):1527-34. doi: 10.1007/s00262-012-1288-3. Epub 2012 Jun 17. Cancer Immunol Immunother. 2012. PMID: 22706380 Free PMC article. Review.
235 results